Subtype Report on Hodgkin Lymphoma
HL is primarily a curable cancer and with current treatments, 80% to 90% of patients can achieve permanent remission. The mainstay of treatment is multi-agent chemotherapy often in combination with radiation therapy. With high treatment responses, focus is now being made to improve long term morbidity issues.
In the past decade there has been a greater understanding of the tumour microenvironment and the overall biology of HL. The discovery of the B-cell identity of HRS and its signaling pathways have the potential to be exploited therapeutically.
It is imperative that novel therapies are made available to all patients no matter where they live. There are huge discrepancies in access and outcome between countries and regions.
Click here to view the report.